Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals

Neurology. 2020 Sep 15;95(11):505. doi: 10.1212/WNL.0000000000010513.
No abstract available

Publication types

  • Comment

MeSH terms

  • Biomarkers
  • Humans
  • Immunologic Factors / adverse effects
  • L-Selectin*
  • Leukoencephalopathy, Progressive Multifocal* / chemically induced
  • Natalizumab / adverse effects
  • Prospective Studies

Substances

  • Biomarkers
  • Immunologic Factors
  • Natalizumab
  • L-Selectin